Can hypothyroidism lead to obesity

Drugs used in the past to treat Obesity

Drugs Used in Past (Year of Introduction)	Year of Discontinuation	Cause of Discontinuation
Thyroid hormone	Off label use till 1980s despite toxicity	Hyperthyroidism, cardiac arrhythmias, and sudden death
Fenfluramine + phentermine (1992)	1997	Valvular heart disease
Phenylpropanolamine (available since 1970)	2000	Hemorrhagic stroke
Rimonabant(available            in UK and other European countries since 2006 for long term treatment of obesity)	EMEA               withdrew marketing authorization in 2009 Failed to get US-FDA approval due to safety factors	Psychiatric disorders, depression and suicidal ideation
Sibutramine                (popular antiobesity drug used since 1997)	2010	Increase in risk of major adverse cardiovascular events (a composite of non-fatal heart attack, non-fatal stroke, resuscitation               after cardiac arrest and cardiovascular death)

(Abbreviation = FDA: Food and Drug Administration; EMEA= European Medicine Agency)

The only currently approved long-term therapy for obesity in the world is not only having limited efficacy, but is also associated with number of side effects. This history of weight-loss pharmacotherapy highlights the need for new, safer, and more effective approaches to treat and prevent obesity.